Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR: Sacituzumab tirumotecan in ADC-pretreated advanced urothelial carcinoma
ChiCTR2600123610Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in transitional cell carcinoma (TCC), sponsored by Peking University Third Hospital. Primary endpoints: Objective Response Rate (ORR), Progression-Free Survival (PFS) and 2 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2600123610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123610.